<article article-type="research-article"> 
 <!--?properties open_acces=""?--> 
 <!-- Original-type: oa--> 
 <front> 
  <journal-meta> 
   <journal-id journal-id-type="nlm-ta">
     Br J Cancer 
   </journal-id> 
   <journal-h3>
     British Journal of Cancer 
   </journal-h3> 
   <issn pub-type="ppub">
     0007-0920 
   </issn> 
   <issn pub-type="epub">
     1532-1827 
   </issn> 
   <publisher> 
    <publisher-name>
      Nature Publishing Group 
    </publisher-name> 
   </publisher> 
  </journal-meta> 
  <article-meta> 
   <article-id pub-id-type="pmid">
     19238633 
   </article-id> 
   <article-id pub-id-type="pmc">
     2538768 
   </article-id> 
   <article-id pub-id-type="pii">
     6604629 
   </article-id> 
   <article-id pub-id-type="doi">
     10.1038/sj.bjc.6604629 
   </article-id> 
   <article-categories> 
    <subj-group subj-group-type="heading"> 
     <subject>
       Molecular Diagnostics 
     </subject> 
    </subj-group> 
   </article-categories> 
   <h3-group> 
    <article-h3>
      Comparison of 
     <italic>
       EGFR 
     </italic> and 
     <italic>
       K-RAS 
     </italic> gene status between primary tumours and corresponding metastases in NSCLC 
    </article-h3> 
   </h3-group> 
   <contrib-group> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Kalikaki 
      </surname> 
      <given-names>
        A 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Koutsopoulos 
      </surname> 
      <given-names>
        A 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Trypaki 
      </surname> 
      <given-names>
        M 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Souglakos 
      </surname> 
      <given-names>
        J 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Stathopoulos 
      </surname> 
      <given-names>
        E 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Georgoulias 
      </surname> 
      <given-names>
        V 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Mavroudis 
      </surname> 
      <given-names>
        D 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Voutsina 
      </surname> 
      <given-names>
        A 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
     <xref ref-type="corresp" rid="caf1">
       * 
     </xref> 
    </contrib> 
   </contrib-group> 
   <aff id="aff1"> 
    <label>1</label> 
    <institution>
      Laboratory of Tumor Cell Biology, School of Medicine, University of Crete 
    </institution> Heraklion, Crete, 
    <country>
      Greece 
    </country> 
   </aff> 
   <aff id="aff2"> 
    <label>2</label> 
    <institution>
      Department of Pathology, University General Hospital of Heraklion 
    </institution> Heraklion, Crete, 
    <country>
      Greece 
    </country> 
   </aff> 
   <aff id="aff3"> 
    <label>3</label> 
    <institution>
      Department of Medical Oncology, University General Hospital of Heraklion 
    </institution> Heraklion, Crete, 
    <country>
      Greece 
    </country> 
   </aff> 
   <author-notes> 
    <corresp id="caf1"> 
     <label>*</label>Author for correspondence: 
     <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:georgsec@med.uoc.gr">
       georgsec@med.uoc.gr 
     </email> 
    </corresp> 
   </author-notes> 
   <pub-date pub-type="epub"> 
    <day>
      26 
    </day> 
    <month>
      08 
    </month> 
    <year>
      2008 
    </year> 
   </pub-date> 
   <pub-date pub-type="collection"> 
    <day>
      09 
    </day> 
    <month>
      09 
    </month> 
    <year>
      2008 
    </year> 
   </pub-date> 
   <pub-date pub-type="ppub"> 
    <day>
      16 
    </day> 
    <month>
      9 
    </month> 
    <year>
      2008 
    </year> 
   </pub-date> 
   <volume>
     99 
   </volume> 
   <issue>
     6 
   </issue> 
   <fpage>
     923 
   </fpage> 
   <lpage>
     929 
   </lpage> 
   <history> 
    <date date-type="received"> 
     <day>
       02 
     </day> 
     <month>
       05 
     </month> 
     <year>
       2008 
     </year> 
    </date> 
    <date date-type="rev-recd"> 
     <day>
       01 
     </day> 
     <month>
       08 
     </month> 
     <year>
       2008 
     </year> 
    </date> 
    <date date-type="accepted"> 
     <day>
       01 
     </day> 
     <month>
       08 
     </month> 
     <year>
       2008 
     </year> 
    </date> 
   </history> 
   <copyright-statement>
     Copyright 2008, Cancer Research UK 
   </copyright-statement> 
   <copyright-year>
     2008 
   </copyright-year> 
   <permissions> 
    <copyright-holder>
      Cancer Research UK 
    </copyright-holder> 
   </permissions> 
   <abstract>
    <h3>Abstract</h3> 
    <p>In non-small-cell lung cancer (NSCLC), epidermal growth factor receptor ( 
     <italic>
       EGFR 
     </italic>) and 
     <italic>
       K-RAS 
     </italic> mutations of the primary tumour are associated with responsiveness and resistance to tyrosine kinase inhibitors (TKIs), respectively. However, the 
     <italic>
       EGFR 
     </italic> and 
     <italic>
       K-RAS 
     </italic> mutation status in metastases is not well studied. We compared the mutation status of these genes between the primary tumours and the corresponding metastases of 25 patients. Epidermal growth factor receptor and 
     <italic>
       K-RAS 
     </italic> mutation status was different between primary tumours and corresponding metastases in 7 (28%) and 6 (24%) of the 25 patients, respectively. Among the 25 primary tumours, three ‘hotspot' and two non-classical 
     <italic>
       EGFR 
     </italic> mutations were found; none of the corresponding metastases had the same mutation pattern. Among the five (20%) 
     <italic>
       K-RAS 
     </italic> mutations detected in the primary tumours, two were maintained in the corresponding metastasis. Epidermal growth factor receptor and 
     <italic>
       K-RAS 
     </italic> mutations were detected in the metastatic tumours of three (12%) and five (20%) patients, respectively. The expressions of EGFR and phosphorylated EGFR showed 10 and 50% discordance, in that order. We conclude that there is substantial discordance in 
     <italic>
       EGFR 
     </italic> and 
     <italic>
       K-RAS 
     </italic> mutational status between the primary tumours and corresponding metastases in patients with NSCLC and this might have therapeutic implications when treatment with TKIs is considered.</p> 
   </abstract> 
   <kwd-group> 
    <kwd> 
     <italic>
       EGFR 
     </italic> 
    </kwd> 
    <kwd> 
     <italic>
       K-RAS 
     </italic> 
    </kwd> 
    <kwd>
      mutations 
    </kwd> 
    <kwd>
      primary tumour 
    </kwd> 
    <kwd>
      metastasis 
    </kwd> 
    <kwd>
      NSCLC 
    </kwd> 
   </kwd-group> 
  </article-meta> 
 </front> 
 <p>Lung cancer is the most frequent solid tumour and represents the leading cause of cancer death throughout the developed world. Almost 70% of patients with non-small-cell lung carcinoma (NSCLC) present with locally advanced or metastatic disease at the time of diagnosis. Non-small-cell lung carcinoma is characterised by the accumulation of multiple genetic alterations ( 
  <xref ref-type="other" rid="bib30">
    Marsit 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib49">
    Yokota and Kohno, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib15">
    Garnis 
   <italic>
     et al 
   </italic>, 2006 
  </xref>). Mutations within the tyrosine kinase domain of epidermal growth factor receptor ( 
  <italic>
    EGFR 
  </italic>) account for increased sensitivity to tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib) and they are associated with prolonged overall survival ( 
  <xref ref-type="other" rid="bib29">
    Lynch 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib32">
    Paez 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib36">
    Perez-Soler 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib7">
    Chou 
   <italic>
     et al 
   </italic>, 2005 
  </xref>; 
  <xref ref-type="other" rid="bib41">
    Taron 
   <italic>
     et al 
   </italic>, 2005 
  </xref>; 
  <xref ref-type="other" rid="bib19">
    Hirsch, 2006 
  </xref>). However, the point mutation T790M and an insertion mutation in exon 20 were associated with resistance to TKIs ( 
  <xref ref-type="other" rid="bib16">
    Gazdar and Minna, 2005 
  </xref>). Furthermore, recent studies have shown that the expression of EGFR as assessed by gene copy number, mRNA and protein levels could be used to predict responsiveness to therapy with TKIs ( 
  <xref ref-type="other" rid="bib21">
    Hirsch 
   <italic>
     et al 
   </italic>, 2005 
  </xref>; 
  <xref ref-type="other" rid="bib41">
    Taron 
   <italic>
     et al 
   </italic>, 2005 
  </xref>; 
  <xref ref-type="other" rid="bib9">
    Dacic 
   <italic>
     et al 
   </italic>, 2006 
  </xref>; 
  <xref ref-type="other" rid="bib11">
    Dziadziuszko 
   <italic>
     et al 
   </italic>, 2006 
  </xref>; 
  <xref ref-type="other" rid="bib12">
    Endo 
   <italic>
     et al 
   </italic>, 2006 
  </xref>). In addition, several clinicopathological characteristics, such as adenocarcinoma histology, non-smoking history, female gender and Asian origin, are also associated with a higher probability of response to TKIs, whereas the presence of 
  <italic>
    K-RAS 
  </italic> mutations seems to be correlated with primary resistance to these agents ( 
  <xref ref-type="other" rid="bib42">
    Tokumo 
   <italic>
     et al 
   </italic>, 2005 
  </xref>; 
  <xref ref-type="other" rid="bib45">
    Tsao 
   <italic>
     et al 
   </italic>, 2005 
  </xref>; 
  <xref ref-type="other" rid="bib47">
    van Zandwijk 
   <italic>
     et al 
   </italic>, 2007 
  </xref>). Thus, an emerging issue concerning EGFR-targeted therapy is to identify the best method for selecting patients who are more likely to benefit from EGFR inhibition.</p> 
 <p>Advanced NSCLC metastasises systemically to diverse sites, such as the brain, bone, adrenal glands and liver. The classical model for the metastatic process suggests that most cells of a given primary tumour have low metastatic potential and only a few cells acquire enough somatic mutations to become metastatic ( 
  <xref ref-type="other" rid="bib2">
    Bernards and Weinberg, 2002 
  </xref>). An alternative model proposes that the metastatic potential is encoded in the mass of a given primary tumour that has progressed to a pre-metastatic state, after which metastases may randomly occur without any further gene expression changes ( 
  <xref ref-type="other" rid="bib46">
    van ‘t Veer 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib23">
    Hynes, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib48">
    Van't Veer and Weigelt, 2003 
  </xref>). Taking into account these two models, a critical issue for the treatment of metastatic NSCLC is the question of genetic variability and differences between the primary tumour and the corresponding metastases. In the majority of studies, 
  <italic>
    EGFR 
  </italic> and 
  <italic>
    K-RAS 
  </italic> status was determined on the primary tumours and there are very few data concerning those of corresponding metastases ( 
  <xref ref-type="other" rid="bib24">
    Italiano 
   <italic>
     et al 
   </italic>, 2006 
  </xref>; 
  <xref ref-type="other" rid="bib31">
    Matsumoto 
   <italic>
     et al 
   </italic>, 2006 
  </xref>). Therefore, it is unclear whether the same 
  <italic>
    EGFR 
  </italic> and 
  <italic>
    K-RAS 
  </italic> mutations are also present in the metastatic lesions or whether clones with different mutations are responsible for the generation of metastases.</p> 
 <p>In this study, the mutation status of 
  <italic>
    EGFR 
  </italic> and 
  <italic>
    K-RAS 
  </italic> as well as the EGFR and p-EGFR expressions on the primary tumours and the corresponding metastatic lesions were evaluated in 25 patients with advanced NSCLC. The objective of this study was to investigate the prevalence of 
  <italic>
    EGFR 
  </italic> and 
  <italic>
    K-RAS 
  </italic> mutations in metastases and to examine whether these mutations and the EGFR expression patterns are discordant between the primary tumours and the corresponding metastases. Secondary objectives were to explore whether the EGFR expression pattern correlated to 
  <italic>
    EGFR 
  </italic> and/or 
  <italic>
    K-RAS 
  </italic> mutations in both the primary tumours and corresponding metastases.</p> 
 <sec sec-type="methods"> 
  <h3>Patients and methods</h3> 
  <sec> 
   <h3>Patients</h3> 
   <p>Patients, aged &gt;18 years old, with histologically confirmed NSCLC who underwent biopsy or surgical excision of the primary tumour and the corresponding metastases were included in this retrospective analysis. Histological type was determined according to the World Health Organization criteria, and the stage of the disease corresponds to that of the time of primary diagnosis. Smoking history was obtained during the patient's first evaluation. All patients gave their informed consent for using their tumour sample for molecular and pathologic analysis. The study has been approved by the Ethics and Scientific Committees of our institution.</p> 
  </sec> 
  <sec> 
   <h3>DNA extraction and mutation analysis</h3> 
   <p>All tumour samples were formalin-fixed paraffin-embedded tissues. Sections of a paraffin block corresponding to one representative area of the tumour were stained with haematoxylin/eosin, and the presence of tumour tissue was verified by an experienced pathologist. Subsequently, tissue samples from at least three serial sections were microdissected (piezo power Eppendorf Microdissector; Eppendorf, Germany) to ensure that specimens contained at least 80% tumour cells; sections of 5? 
    <italic>
      ? 
    </italic>m thickness were also collected from adjacent normal tissue when available, extracted with xylene and ethanol to remove paraffin and placed in 1% SDS/proteinase K (10?mg?ml<sup>?1</sup>) at 56°C overnight. DNA was extracted using the MasterPure Complete DNA/RNA Purification kit (Epicentre Biotechnologies, Madison, WI, USA) according to the manufacturer's instructions. Exons 18, 19, 20 and 21 of the EGFR and exon 1 of K-RAS were sequentially amplified by two rounds of polymerase chain reaction (PCR) and subjected to direct sequencing. The PCR primers for 
    <italic>
      EGFR 
    </italic> amplification were as follows: 155273L23: 5?-TCCCAAACACTCAGTGAAACAAA-3?; 155348L22: 5?-TGGTCTCACAGGACCACTGATT-3?; 154838U22: 5?-TCAGAGCCTGTGTTTCTACCAA-3?; 154899U20: 5?-TCCAAATGAGCTGGCAAGTG-3?; 55634U24: 5?-AAATAATCAGTGTGATTCGTGGAG-3?; 156027L20: 5?-TGTGGAGATGAGCAGGGTCT-3?; 156107L22: 5?-GAGGCCAGTGCTGTCTCTAAGG-3?; 155750U20: 5?-GTGCATCGCTGGTAACATCC-3?; 173160L22: 5?-CAGCTCTGGCTCACACTACCAG-3?; 173076L19: 5?-CATCCTCCCCTGCATGTGT-3?; 172656U22: 5?-GCAGCGGGTTACATCTTCTTTC-3?; and 172747U19: 5?-GCT CAGAGCCTGGCATGAA-3?. The PCR primers for 
    <italic>
      K-RAS 
    </italic> amplification were as follows: RASU1: 5?-AGGCCTGCTGAAAATGACTGAATA-3?; RASL1: 5?-CTGTATCAAAGAATGGTCCTGCAC-3?; RASU2: 5?-AAAATGACTGAATATAAACTTGTGG-3?; RASL2: 5?-CTCTATTGTTGGATCATATTCGTC-3?. The first PCR was carried out in a total volume of 10? 
    <italic>
      ? 
    </italic>l contained 1/10 of the extracted genomic DNA using 1?U of Platinum Taq DNA polymerase (Invitrogen Corporation, Carlsbad, CA, USA). The initial denaturing step was at 94°C for 15?min, followed by 35 cycles of denaturing step at 94°C for 20?s, annealing step at 60°C for 30?s and extension step at 72°C for 1?min, ending with a final extension step at 72°C for 7?min. Nested PCR was carried out in a total volume of 20? 
    <italic>
      ? 
    </italic>l and the conditions were identical to the first PCR. The PCR products are directly sequenced by dye terminator sequencing (ABI BigDye Terminator kit, v3.1, Applied Biosystems, Foster City, CA, USA), purified by ethanol precipitation and separated by capillary electrophoresis on an ABI 3100 Avant genetic analyzer (Applied Biosystems). Sequence analysis was carried out by Seqscape software (Applied Biosystems) and manually by two reviewers (AK and AV). All sequence variations were confirmed by sequencing in both directions and by an independent PCR amplification when sufficient material was available.</p> 
   <p>The sensitivity of our methodology was evaluated by determining the minimum frequency of 
    <italic>
      EGFR 
    </italic> and 
    <italic>
      K-RAS 
    </italic> mutations required for detection in our system. This was accomplished by performing mixing experiments using cell lines with and without 
    <italic>
      EGFR 
    </italic> (H2073-wt- 
    <italic>
      EGFR 
    </italic> and HCC827-Del19- 
    <italic>
      EGFR 
    </italic>) or 
    <italic>
      K-RAS 
    </italic> (H2073-wt- 
    <italic>
      K-RAS 
    </italic> and A549-G12D- 
    <italic>
      K-RAS 
    </italic>) mutations. These experiments demonstrated that the Del19 and 
    <italic>
      K-RAS 
    </italic> mutations could be detected when present in 10 and 20% of the cells in the sample, respectively (data not shown).</p> 
  </sec> 
  <sec> 
   <h3>Immunohistochemistry for EGFR</h3> 
   <p>The paraffin-embedded tissues were cut at 4? 
    <italic>
      ? 
    </italic>m thickness and were deposited on SuperFrost/Plus Slides (O.Kindler GmbH, Freiburg, Germany). After deparaffinisation, the slides for EGFR were treated with proteinase K (Code S3020, DakoCytomation, Glostrup, Denmark) for 5?min at room temperature, and those for p-EGFR were treated with EDTA at pH 8 in a microwave oven three times for 5?min at 500?W for antigen retrieval. The primary anti-EGFR antibody (mouse monoclonal, clone H11, code M3563, DakoCytomation) was used at a dilution of 1?:?50 (v/v) and incubated for 1?h at room temperature. The primary anti-phospho-EGFR antibody (rabbit monoclonal, pY1173-EGFR, code no. 4407, Cell Signalling, Danvers, MA, USA) was used at a dilution of 1?:?200 (v/v) and incubated overnight at 4°C. For the detection of antigen-antibody reaction, the UltraVision detection system AP Polymer kit (Cat no. TL-125-AL, Lab Vision, Fremont, CA, USA) was used according to the manufacturer's instructions. Fast red was used as chromogen for 20?min; the sections were counterstained with Mayer's haematoxylin for 3?min, subsequently rinsed in ammonium and finally mounted with glycergel. A positive (an NSCLC tumour specimen with known positivity) and a negative (omission of primary antibody) control were used. The stained sections were independently evaluated by two pathologists (AK and ES). Immunoreactions of EGFR were graded as 3+ when strong complete membrane staining was observed in more than 10% of the tumour cells, as 2+ when more than 10% of the tumour cells showed weak-to-moderate complete membrane staining, as 1+ when partially, faint membrane stain was detected in more than 10% of the tumour cells and as 0 when no staining at all or membrane staining in less than 10% of the tumour cells was observed. In this study, we arbitrarily classified EGFR expression status in two subsets; the 2+ or 3+ signals were considered as EGFR overexpression and the 0 or 1+ signals as non-expression ( 
    <xref ref-type="other" rid="bib25">
      Koutsopoulos 
     <italic>
       et al 
     </italic>, 2007 
    </xref>).</p> 
   <p>A paraffin block from the HCC827 lung epithelial adenocarcinoma cell line and commercially available positive controls (SignalSlide Phospho-EGF Receptor (Tyr1173) IHC Controls, code no. 8102, Cell Signalling) was used to validate the antibody for p-EGFR. pY1173-EGFR immunostaining was mainly membranous and was graded as 0 (&lt;5% positive cells), 1+ (5–19% positive cells), 2+ (20–50% positive cells) and 3+ (&gt;50% positive cells) ( 
    <xref ref-type="other" rid="bib8">
      Cortas 
     <italic>
       et al 
     </italic>, 2007 
    </xref>).</p> 
  </sec> 
  <sec> 
   <h3>Statistical analysis</h3> 
   <p>McNemar test was used to compare the 
    <italic>
      EGFR 
    </italic> and 
    <italic>
      K-RAS 
    </italic> status between primary tumours and related metastatic sites. Differences were considered statistically significant when the 
    <italic>
      P 
    </italic>-value was &lt;0.05. All statistical tests were two-sided.</p> 
  </sec> 
 </sec> 
 <sec> 
  <h3>Results</h3> 
  <sec> 
   <h3>Patient characteristics</h3> 
   <p>Twenty-two (88%) patients were men and 22 (88%) were active or former smokers and their median age was 55 years (range, 41–70). Eighteen (72%) patients had adenocarcinomas (ADC) and 21 (84%) patients had stage III or IV disease. Among the 50 samples analysed (25 primary tumours and 25 metastases), 26 (52%) samples were surgical and 24 (48%) biopsies. The primary tumour tissue was the lung ( 
    <italic>
      n 
    </italic>=25 patients); and the origin of the metastatic sample was lung ( 
    <italic>
      n 
    </italic>=9 patients), thoracic wall ( 
    <italic>
      n 
    </italic>=5 patients), adrenal gland ( 
    <italic>
      n 
    </italic>=4 patients), brain ( 
    <italic>
      n 
    </italic>=3 patients), bone ( 
    <italic>
      n 
    </italic>=2 patients), liver ( 
    <italic>
      n 
    </italic>=1 patient) and skin ( 
    <italic>
      n 
    </italic>=1 patient). Metastases were metachronous in all cases; the median time elapsed between resection of the primary tumour and the corresponding metastatic site was 30 months (range, 4–143). The patients' clinicopathologic characteristics are presented in 
    <xref ref-type="table" rid="tbl1">
      Table 1 
    </xref>. Nine (36%) patients were treated with gefitinib in the context of an Expanded Access Program ( 
    <xref ref-type="table" rid="tbl2">
      Table 2 
    </xref>).</p> 
  </sec> 
  <sec> 
   <h3> 
    <italic>
      EGFR 
    </italic> mutation status of the primary tumours and the corresponding metastasis</h3> 
   <p>The 
    <italic>
      EGFR 
    </italic> mutation status of the primary tumours and the corresponding metastases is presented in 
    <xref ref-type="table" rid="tbl2">
      Table 2 
    </xref>. Epidermal growth factor receptor mutations were detected in the primary tumours of five (20%) patients; of these, three of them were the well-characterised ‘hotspot' mutations in exon 19 (Del746-750 and E746V; case nos. 20, 23 and 18) and the remaining two were novel point mutations in exons 18 and 21 (L692P and G857E; case nos. 17 and 19), respectively. The corresponding metastases of the Del746-750 (case no. 23), E746V (no. 18), L692P (no. 17) and G857E (no. 19) mutant primary tumours were wild type with respect to 
    <italic>
      EGFR 
    </italic> mutation status. Epidermal growth factor receptor mutations were detected in the metastatic tumours of three (12%) patients ( 
    <xref ref-type="table" rid="tbl2">
      Table 2 
    </xref>). The metastasis of one of these patients showed the same 
    <italic>
      EGFR 
    </italic> mutation (Del19) as the primary tumour as well as an additional one, the T790M in exon 20 (no. 20); conversely, the other two patients carried two novel mutations in exon 18 (L692P and V717A; no. 12) and the T847A (no. 13) in exon 21, which could not be detected in the patients' primary tumour samples. We have confirmed that the non-classical mutations detected in our series are not single nucleotide polymorphisms by mutation analysis of matched normal tissue or blood (data not shown).</p> 
   <p>Consequently, the 
    <italic>
      EGFR 
    </italic> gene status could be classified as: (i) 
    <italic>
      EGFR 
    </italic> wild type in both primary tumour and metastasis ( 
    <italic>
      n 
    </italic>=18 patients; 72%), and (ii) 
    <italic>
      EGFR 
    </italic> mutations detected only in the primary tumour ( 
    <italic>
      n 
    </italic>=4 patients; 16%) or the metastases ( 
    <italic>
      n 
    </italic>=2 patients; 8%) or both ( 
    <italic>
      n 
    </italic>=1 patient; 4%). Therefore, 
    <italic>
      EGFR 
    </italic> mutation status showed a discordance of 28% (7 of 25 patients) (McNemar test, 
    <italic>
      P 
    </italic>=0.688) between the primary tumour and corresponding metastasis ( 
    <xref ref-type="table" rid="tbl3">
      Table 3 
    </xref>).</p> 
  </sec> 
  <sec> 
   <h3>EGFR and p-EGFR expression by IHC in the primary tumour and the corresponding metastases</h3> 
   <p>Én 19 patients sufficient tumour tissue was available for immunohistochemical analysis of EGFR ( 
    <xref ref-type="table" rid="tbl2">
      Tables 2 
    </xref> and 
    <xref ref-type="table" rid="tbl4">
      4 
    </xref>). The incidence of EGFR overexpression (grade 2+, 3+) was 26.5% in both primary and metastatic tumours. Concordance between the primary tumour and the corresponding metastases was observed in 17 (89.5) patients (Cohen's Kappa=0.729, 
    <italic>
      P 
    </italic>=0.001) and among them EGFR was overexpressed in four (21.1%). Discordance was observed in two (10.5%) patients (nos. 14 and 15) (McNemar test, 
    <italic>
      P 
    </italic>=1). Evaluable paired tissue specimens for p-EGFR analysis by IHC were available in 16 patients. Three out of 16 (18.8%) primary and seven out of 16 (43.8%) metastatic tumours expressed phosphorylated EGFR (pY1173-EGFR-positive). Discordance between the primary and metastatic tumours was observed in eight (50%) patients (McNemar test, 
    <italic>
      P 
    </italic>=1) ( 
    <xref ref-type="table" rid="tbl2">
      Tables 2 
    </xref> and 
    <xref ref-type="table" rid="tbl4">
      4 
    </xref>). There was no correlation between the expression of EGFR and pY1173-EGFR. In order to confirm our findings, we repeated the immunohistochemistry from serial sections in all tumour specimens that exhibited EGFR-negative and p-EGFR-positive staining and the obtained results were identical. Epidermal growth factor receptor gene copy number was also investigated by fluorescence 
    <italic>
      in situ 
    </italic> hybridisation in eight patients (nos. 2, 5, 7, 9, 10, 13, 19 and 24) for whom paired tissue specimens were available; amplification of 
    <italic>
      EGFR 
    </italic> gene was not detected in any of these tumour specimens.</p> 
  </sec> 
  <sec> 
   <h3> 
    <italic>
      K-RAS 
    </italic> mutation status of the primary tumours and the corresponding metastases</h3> 
   <p>Primary and metastatic tumours were also assessed for 
    <italic>
      K-RAS 
    </italic> mutations ( 
    <xref ref-type="table" rid="tbl2">
      Table 2 
    </xref>). 
    <italic>
      K-RAS 
    </italic> mutations were detected in the primary tumours of five (20%) patients (nos. 8, 10, 22, 23 and 25) and in the metastatic tumours of five (20%) patients (nos. 9, 10, 11, 16 and 23), respectively. Two patients (nos. 10 and 23) carried the same 
    <italic>
      K-RAS 
    </italic> mutations in both primary and metastatic tumours ( 
    <xref ref-type="table" rid="tbl2">
      Table 2 
    </xref>). One of them (case no. 23) carried the Del746-750 EGFR mutation in the primary tumour but not in metastasis. This was confirmed by three independent PCRs from three genomic DNAs extracted from serial sections of the paraffin blocks. Discordance in 
    <italic>
      K-RAS 
    </italic> mutation status between the primary tumours and the corresponding metastases was observed in six (24%) patients (McNemar test, 
    <italic>
      P 
    </italic>=1) ( 
    <xref ref-type="table" rid="tbl3">
      Table 3 
    </xref>).</p> 
  </sec> 
  <sec> 
   <h3>Response to gefitinib according to 
    <italic>
      EGFR 
    </italic> and 
    <italic>
      K-RAS 
    </italic> mutation status</h3> 
   <p>Nine patients received gefitinib as first (nos. 23 and 18), third (nos. 15, 16, 19 20 and 22) or fourth (nos. 14 and 17) line treatment. Three patients received gefitinib before the biopsy of metachronous metastases (nos. 17, 18 and 20) and six received gefitinib after the biopsy of metastases (nos. 14, 15, 16, 19, 22 and 23). Five patients (56%) achieved stable disease and four (44%) progressive disease ( 
    <xref ref-type="table" rid="tbl2">
      Table 2 
    </xref>). All patients who experienced progressive disease on gefitinib were wild type regarding the 
    <italic>
      EGFR 
    </italic> mutation status in both primary tumours and metastases (nos. 14, 15, 16, and 22), of these, two patients carried 
    <italic>
      K-RAS 
    </italic> mutations in the primary tumour (no. 22) or metastasis (no. 16). All the five patients with stable disease on gefitinib carried EGFR mutations in their primary tumours (nos. 17, 18, 19, 20 and 23). Of these, three patients carried the well-characterised activating mutations in exon 19 (nos. 18, 20 and 23) and two carried 
    <italic>
      EGFR 
    </italic> mutations of unknown function (nos. 17 and 19). Patient nos. 18 and 20 who received gefitinib before metachronous metastasis developed metastatic tumours, which were either wild type in respect to 
    <italic>
      EGFR 
    </italic> mutation status (no. 18) or had acquired resistance because of the T790M 
    <italic>
      EGFR 
    </italic> mutation (no. 20). Patient no. 23, who received gefitinib after metastasis, carried both 
    <italic>
      EGFR 
    </italic> and 
    <italic>
      K-RAS 
    </italic> mutations in the primary tumour and the same 
    <italic>
      K-RAS 
    </italic> mutation in metastasis.</p> 
  </sec> 
 </sec> 
 <sec> 
  <h3>Discussion</h3> 
  <p>Several studies have shown that activating 
   <italic>
     EGFR 
   </italic> mutations in exons 18, 19 and 21 have been associated with a 75–95% objective response rate with EGFR TKIs, whereas the 
   <italic>
     K-RAS 
   </italic> mutations were associated with a lack of sensitivity to these agents ( 
   <xref ref-type="other" rid="bib34">
     Pao 
    <italic>
      et al 
    </italic>, 2005 
   </xref>; 
   <xref ref-type="other" rid="bib38">
     Sharma 
    <italic>
      et al 
    </italic>, 2007 
   </xref>). Epidermal growth factor receptor gene amplification and protein expression have also been considered as predictors of clinical benefit with gefitinib ( 
   <xref ref-type="other" rid="bib20">
     Hirsch 
    <italic>
      et al 
    </italic>, 2006 
   </xref>). However, in clinical studies, a significant percentage of patients presented clinical benefit when treated with TKIs irrespective of the expression and mutational status of 
   <italic>
     EGFR 
   </italic> ( 
   <xref ref-type="other" rid="bib38">
     Sharma 
    <italic>
      et al 
    </italic>, 2007 
   </xref>). As, in most studies, 
   <italic>
     EGFR 
   </italic> expression and mutations were determined on the primary tumour, the observed clinical benefit of patients with wild-type 
   <italic>
     EGFR 
   </italic> or the absence of response to TKIs of patients with 
   <italic>
     EGFR 
   </italic> mutations could be due to discordance in the 
   <italic>
     EGFR 
   </italic> mutation status or expression between the primary tumour and the corresponding metastasis.</p> 
  <p>This study demonstrated the existence of a significant discordance of 
   <italic>
     EGFR 
   </italic> and 
   <italic>
     K-RAS 
   </italic> mutations occurring in primary tumours and their corresponding metastases in patients with NSCLC. The discordance in 
   <italic>
     EGFR 
   </italic> mutation status was 28% and that in 
   <italic>
     K-RAS 
   </italic> was 24%. Similarly, two other studies in paired NSCLC tumours showed a discordance of 32 and 27% regarding the 
   <italic>
     EGFR 
   </italic> gene copy number ( 
   <xref ref-type="other" rid="bib24">
     Italiano 
    <italic>
      et al 
    </italic>, 2006 
   </xref>; 
   <xref ref-type="other" rid="bib3">
     Bozzetti 
    <italic>
      et al 
    </italic>, 2008 
   </xref>), whereas another study including six NSCLC patients of Asian ethnicity reported a 100% concordance in regard to 
   <italic>
     EGFR 
   </italic> mutation status ( 
   <xref ref-type="other" rid="bib31">
     Matsumoto 
    <italic>
      et al 
    </italic>, 2006 
   </xref>). This discrepancy could be related to the different sites of the metastatic tumours analysed in this study (five different distant metastases), whereas in the Matsumoto's 
   <italic>
     et al 
   </italic> study, only tumour samples from brain metastases were included. Diverse sites of metastases in NSCLC probably represent different clonal outgrowths. Alternatively, we cannot exclude that the different ethnicity of patients and/or the different types of 
   <italic>
     EGFR 
   </italic> mutations could be the reason for this discrepancy ( 
   <xref ref-type="other" rid="bib44">
     Tsao 
    <italic>
      et al 
    </italic>, 2006 
   </xref>; 
   <xref ref-type="other" rid="bib33">
     Pallis 
    <italic>
      et al 
    </italic>, 2007 
   </xref>). In this study including only Caucasian patients, three classical activating (Del19 and E746V) and four non-classical mutations (T847A, L692P-V717A, L692P and G857E) were detected, whereas in Matsumoto's 
   <italic>
     et al 
   </italic> study, only classical activating Del19 and L858R mutations were reported. Concerning the non-classical mutations, it is unlikely to represent PCR artifacts, as L692F, T847I and G857E 
   <italic>
     EGFR 
   </italic> mutations have been previously reported ( 
   <xref ref-type="other" rid="bib14">
     Fujimoto 
    <italic>
      et al 
    </italic>, 2005 
   </xref>; 
   <xref ref-type="other" rid="bib45">
     Tsao 
    <italic>
      et al 
    </italic>, 2005 
   </xref>; 
   <xref ref-type="other" rid="bib22">
     Hsieh 
    <italic>
      et al 
    </italic>, 2006 
   </xref>). Furthermore, the expression of phosphorylated EGFR (pY1173-EGFR-positive) on tumour cells from metastatic lesions carrying the T847A and L692P-V717A mutations strongly suggests that the former might be activating EGFR mutation. The time elapsed between diagnoses of the primary tumour and corresponding metastasis in patients (nos. 13 and 12) carrying the abovementioned mutations was 74.5 and 10 months, respectively. Therefore, acquisition of new mutations may be developed during the evolution of the metastatic process.</p> 
  <p>The administration of TKIs could be an additional explanation of the observed discordance of 
   <italic>
     EGFR 
   </italic> mutations. Three out of 25 patients received gefitinib before the development of a metachronous metastasis, whereas none of the patients reported in the Matsumoto's 
   <italic>
     et al 
   </italic> study had exposed to TKIs. It is known that NSCLC patients with EGFR-dependent primary tumours when treated with TKIs can develop metastases, in which either the EGFR signalling is negated or resistance is acquired due to secondary 
   <italic>
     EGFR 
   </italic> mutations like T790M or MET amplification ( 
   <xref ref-type="other" rid="bib10">
     Daneshmand 
    <italic>
      et al 
    </italic>, 2003 
   </xref>; 
   <xref ref-type="other" rid="bib16">
     Gazdar and Minna, 2005 
   </xref>; 
   <xref ref-type="other" rid="bib13">
     Engelman 
    <italic>
      et al 
    </italic>, 2007 
   </xref>; 
   <xref ref-type="other" rid="bib28">
     Lutterbach 
    <italic>
      et al 
    </italic>, 2007 
   </xref>). It is interesting to note that in patients who had not been exposed to TKIs before biopsy of metastatic lesions, a 18% (4 out of 22 patients) discordance was observed between primary tumours and related metastases. However, a final explanation of the observed discordance, which cannot be excluded, concerns the low-frequency intratumoral heterogeneity for the occurrence of 
   <italic>
     EGFR 
   </italic> mutations ( 
   <xref ref-type="other" rid="bib37">
     Sakurada 
    <italic>
      et al 
    </italic>, 2008 
   </xref>).</p> 
  <p>Our findings concerning the 
   <italic>
     K-RAS 
   </italic> mutation status are in agreement with a previous study demonstrating that the 
   <italic>
     K-RAS 
   </italic> mutational status of the primary tumour does not always predict the status of bone metastasis in NSCLC ( 
   <xref ref-type="other" rid="bib1">
     Badalian 
    <italic>
      et al 
    </italic>, 2007 
   </xref>). A similar phenomenon was also reported in patients with colorectal cancer ( 
   <xref ref-type="other" rid="bib43">
     Tortola 
    <italic>
      et al 
    </italic>, 2001 
   </xref>). Although 
   <italic>
     K-RAS 
   </italic> mutations seem to be associated with the early development of NSCLC, it cannot be excluded that 
   <italic>
     K-RAS 
   </italic> mutations are lost later during tumour progression ( 
   <xref ref-type="other" rid="bib4">
     Burmer and Loeb, 1989 
   </xref>; 
   <xref ref-type="other" rid="bib26">
     Li 
    <italic>
      et al 
    </italic>, 1994 
   </xref>). This may, in part, explain the discordance in the 
   <italic>
     K-RAS 
   </italic> mutation status between primary tumours and metachronous metastases.</p> 
  <p>Another possibility for the observed discordance in the 
   <italic>
     EGFR 
   </italic> and 
   <italic>
     K-RAS 
   </italic> mutation status could be related to the administered chemotherapy. However, as shown in 
   <xref ref-type="table" rid="tbl1">
     Table 1 
   </xref>, among the 10 patients who had not received any treatment before the mutation analysis of the metastatic lesions, 5 developed metastases with different mutation status from that of the corresponding primary tumours. Thus, although tumour clone selection through the various treatments could be an explanation for the different molecular pattern in the primary tumour and metastatic site, our findings suggest that the metastasis genotype could be different from that of the corresponding primary tumour irrespectively of administered chemotherapy.</p> 
  <p>Previous studies have shown that 
   <italic>
     EGFR 
   </italic> and 
   <italic>
     K-RAS 
   </italic> mutations are mutually exclusive, suggesting the presence of different pathways of lung carcinogenesis. However, as previously reported, our data show that 
   <italic>
     K-RAS 
   </italic> mutation may coexist with 
   <italic>
     EGFR 
   </italic> mutation ( 
   <xref ref-type="other" rid="bib14">
     Fujimoto 
    <italic>
      et al 
    </italic>, 2005 
   </xref>; 
   <xref ref-type="other" rid="bib18">
     Han 
    <italic>
      et al 
    </italic>, 2006 
   </xref>). Among the five patients with 
   <italic>
     EGFR 
   </italic> mutations in primary tumours, one patient concomitantly had 
   <italic>
     K-RAS 
   </italic> mutation (G12C with deletion in exon 19). In the metachronous metastasis, only the 
   <italic>
     K-RAS 
   </italic> mutation was retained. This patient received gefitinib after the biopsy of metastatic lesion and had stable disease lasting for 3.5 months. The limited duration of response is compatible with the knowledge that the presence of 
   <italic>
     K-RAS 
   </italic> mutations is associated with resistance to TKIs.</p> 
  <p>In this study, the expression of pY1173-EGFR was different between primary tumours and corresponding metastases in eight (50%) patients, whereas EGFR expression was discordant in two (10%) patients. The apparent lack of correlation between EGFR and p-EGFR expression has been previously reported and could be due to the different scoring systems and different sensitivities of antibodies used to evaluate the EGFR and p-EGFR expressions ( 
   <xref ref-type="other" rid="bib17">
     Han 
    <italic>
      et al 
    </italic>, 2005 
   </xref>). It is well known that overexpression of 
   <italic>
     EGFR 
   </italic> is associated with Tyr phosphorylation of the receptor proteins and that mutations in the kinase domain may cause constitutive phosphorylation of EGFR ( 
   <xref ref-type="other" rid="bib6">
     Chen 
    <italic>
      et al 
    </italic>, 2006 
   </xref>). However, biochemical studies have shown that variable phosphorylation rates were associated with different tyrosine phosphorylation sites in the receptor; G719S mutant receptor had less EGF-induced phosphorylation at Y845, Y992, Y1068 and Y1173 than did wild-type EGFR, whereas L858R mutant receptor preferentially phosphorylated at the Y1068 but not at Y1173 ( 
   <xref ref-type="other" rid="bib39">
     Sordella 
    <italic>
      et al 
    </italic>, 2004 
   </xref>; 
   <xref ref-type="other" rid="bib6">
     Chen 
    <italic>
      et al 
    </italic>, 2006 
   </xref>; 
   <xref ref-type="other" rid="bib27">
     Liu 
    <italic>
      et al 
    </italic>, 2007 
   </xref>).</p> 
  <p>Clinical investigations suggested a correlation between a high 
   <italic>
     EGFR 
   </italic> gene copy number and 
   <italic>
     EGFR 
   </italic> mutations ( 
   <xref ref-type="other" rid="bib5">
     Cappuzzo 
    <italic>
      et al 
    </italic>, 2005 
   </xref>; 
   <xref ref-type="other" rid="bib40">
     Takano 
    <italic>
      et al 
    </italic>, 2005 
   </xref>). Our study failed to demonstrate such a correlation probably due to limited number of cases analysed. Evaluable paired tissue specimens for fluorescence 
   <italic>
     in situ 
   </italic> hybridisation analysis were available for eight patients. Among them, two (nos 13 and 19) patients presented different 
   <italic>
     EGFR 
   </italic> mutation status in the primary tumours and corresponding metastases; however, these two patients harbour non-classical 
   <italic>
     EGFR 
   </italic> mutations (T847A and G857E) and did not show different 
   <italic>
     EGFR 
   </italic> amplification patterns between paired samples. On the basis of these findings, at the present time, we consider that only the genetic differences unequivocally distinguish EGFR-dependent tumours, which are likely to be sensitive to TKIs from the tumours that could be resistant to these agents ( 
   <xref ref-type="other" rid="bib35">
     Papadopoulos 
    <italic>
      et al 
    </italic>, 2006 
   </xref>).</p> 
  <p>In conclusion, our findings indicate a substantial discordance of 
   <italic>
     EGFR 
   </italic> and 
   <italic>
     K-RAS 
   </italic> mutations between the primary tumours and the corresponding metastases in NSCLC and underline the need to consider the genotype of both primary and metastatic tumours for selecting patients who will respond to therapy with TKIs.</p> 
 </sec> 
 <back> 
  <ack> 
   <p>This study was supported by a research grant from the Cretan Association for Biomedical Research (CABR).</p> 
  </ack> 
  <ref-list> 
   <ref id="bib1"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Badalian 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Barbai 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Raso 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Derecskei 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Szendroi 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Timar 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status 
     </article-h3> 
     <source />Pathol Oncol Res 
     <year>
       2007 
     </year> 
     <volume>
       13 
     </volume> 
     <fpage>
       99 
     </fpage> 
     <lpage>
       104 
     </lpage> 
     <!--PubMed citation query: 'Pathol Oncol Res||13|99||bib1|'--> 
     <pub-id pub-id-type="pmid">
       17607370 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib2"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Bernards 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weinberg 
       </surname> 
       <given-names>
         RA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       A progression puzzle 
     </article-h3> 
     <source />Nature 
     <year>
       2002 
     </year> 
     <volume>
       418 
     </volume> 
     <fpage>
       823 
     </fpage> 
     <!--PubMed citation query: 'Nature||418|823||bib2|'--> 
     <pub-id pub-id-type="pmid">
       12192390 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib3"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Bozzetti 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tiseo 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lagrasta 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nizzoli 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Guazzi 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Leonardi 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gasparro 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Spiritelli 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rusca 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Carbognani 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Majori 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Franciosi 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rindi 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ardizzoni 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites 
     </article-h3> 
     <source />J Thorac Oncol 
     <year>
       2008 
     </year> 
     <volume>
       3 
     </volume> 
     <fpage>
       18 
     </fpage> 
     <lpage>
       22 
     </lpage> 
     <!--PubMed citation query: 'J Thorac Oncol||3|18||bib3|'--> 
     <pub-id pub-id-type="pmid">
       18166836 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib4"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Burmer 
       </surname> 
       <given-names>
         GC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Loeb 
       </surname> 
       <given-names>
         LA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma 
     </article-h3> 
     <source />Proc Natl Acad Sci USA 
     <year>
       1989 
     </year> 
     <volume>
       86 
     </volume> 
     <fpage>
       2403 
     </fpage> 
     <lpage>
       2407 
     </lpage> 
     <!--PubMed citation query: 'Proc Natl Acad Sci USA||86|2403||bib4|'--> 
    </citation> 
   </ref> 
   <ref id="bib5"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Cappuzzo 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hirsch 
       </surname> 
       <given-names>
         FR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rossi 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bartolini 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ceresoli 
       </surname> 
       <given-names>
         GL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bemis 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haney 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Witta 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Danenberg 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Domenichini 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ludovini 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Magrini 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gregorc 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Doglioni 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sidoni 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tonato 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Franklin 
       </surname> 
       <given-names>
         WA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Crino 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bunn 
       </surname> 
       <given-names>
         PA 
       </given-names> 
       <suffix>
         Jr 
       </suffix> 
      </name> 
      <name> 
       <surname>
         Varella-Garcia 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer 
     </article-h3> 
     <source />J Natl Cancer Inst 
     <year>
       2005 
     </year> 
     <volume>
       97 
     </volume> 
     <fpage>
       643 
     </fpage> 
     <lpage>
       655 
     </lpage> 
     <!--PubMed citation query: 'J Natl Cancer Inst||97|643||bib5|'--> 
     <pub-id pub-id-type="pmid">
       15870435 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib6"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         YR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fu 
       </surname> 
       <given-names>
         YN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lin 
       </surname> 
       <given-names>
         CH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yang 
       </surname> 
       <given-names>
         ST 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hu 
       </surname> 
       <given-names>
         SF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         YT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsai 
       </surname> 
       <given-names>
         SF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Huang 
       </surname> 
       <given-names>
         SF 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants 
     </article-h3> 
     <source />Oncogene 
     <year>
       2006 
     </year> 
     <volume>
       25 
     </volume> 
     <fpage>
       1205 
     </fpage> 
     <lpage>
       1215 
     </lpage> 
     <!--PubMed citation query: 'Oncogene||25|1205||bib6|'--> 
     <pub-id pub-id-type="pmid">
       16205628 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib7"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Chou 
       </surname> 
       <given-names>
         TY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chiu 
       </surname> 
       <given-names>
         CH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Li 
       </surname> 
       <given-names>
         LH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hsiao 
       </surname> 
       <given-names>
         CY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tzen 
       </surname> 
       <given-names>
         CY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chang 
       </surname> 
       <given-names>
         KT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         YM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Perng 
       </surname> 
       <given-names>
         RP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsai 
       </surname> 
       <given-names>
         SF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsai 
       </surname> 
       <given-names>
         CM 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2005 
     </year> 
     <volume>
       11 
     </volume> 
     <fpage>
       3750 
     </fpage> 
     <lpage>
       3757 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||11|3750||bib7|'--> 
     <pub-id pub-id-type="pmid">
       15897572 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib8"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Cortas 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Eisenberg 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fu 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kern 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Patrick 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dowlati 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer 
     </article-h3> 
     <source />Lung Cancer 
     <year>
       2007 
     </year> 
     <volume>
       55 
     </volume> 
     <fpage>
       349 
     </fpage> 
     <lpage>
       355 
     </lpage> 
     <!--PubMed citation query: 'Lung Cancer||55|349||bib8|'--> 
     <pub-id pub-id-type="pmid">
       17161498 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib9"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Dacic 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Flanagan 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cieply 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ramalingam 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Luketich 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Belani 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yousem 
       </surname> 
       <given-names>
         SA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma 
     </article-h3> 
     <source />Am J Clin Pathol 
     <year>
       2006 
     </year> 
     <volume>
       125 
     </volume> 
     <fpage>
       860 
     </fpage> 
     <lpage>
       865 
     </lpage> 
     <!--PubMed citation query: 'Am J Clin Pathol||125|860||bib9|'--> 
     <pub-id pub-id-type="pmid">
       16690485 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib10"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Daneshmand 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Parolin 
       </surname> 
       <given-names>
         DA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hirte 
       </surname> 
       <given-names>
         HW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Major 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Goss 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stewart 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Batist 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Miller 
       </surname> 
       <given-names>
         WH 
       </given-names> 
       <suffix>
         Jr 
       </suffix> 
      </name> 
      <name> 
       <surname>
         Matthews 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Seymour 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lorimer 
       </surname> 
       <given-names>
         IA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       9 
     </volume> 
     <fpage>
       2457 
     </fpage> 
     <lpage>
       2464 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||9|2457||bib10|'--> 
     <pub-id pub-id-type="pmid">
       12855618 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib11"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Dziadziuszko 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Witta 
       </surname> 
       <given-names>
         SE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cappuzzo 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Park 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tanaka 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Danenberg 
       </surname> 
       <given-names>
         PV 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Baron 
       </surname> 
       <given-names>
         AE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Crino 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Franklin 
       </surname> 
       <given-names>
         WA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bunn 
       </surname> 
       <given-names>
         PA 
       </given-names> 
       <suffix>
         Jr 
       </suffix> 
      </name> 
      <name> 
       <surname>
         Varella-Garcia 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Danenberg 
       </surname> 
       <given-names>
         KD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hirsch 
       </surname> 
       <given-names>
         FR 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2006 
     </year> 
     <volume>
       12 
     </volume> 
     <fpage>
       3078 
     </fpage> 
     <lpage>
       3084 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||12|3078||bib11|'--> 
     <pub-id pub-id-type="pmid">
       16707605 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib12"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Endo 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sasaki 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yano 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kobayashi 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yukiue 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haneda 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Suzuki 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kawano 
       </surname> 
       <given-names>
         O 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fujii 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy 
     </article-h3> 
     <source />Oncol Rep 
     <year>
       2006 
     </year> 
     <volume>
       16 
     </volume> 
     <fpage>
       533 
     </fpage> 
     <lpage>
       541 
     </lpage> 
     <!--PubMed citation query: 'Oncol Rep||16|533||bib12|'--> 
     <pub-id pub-id-type="pmid">
       16865253 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib13"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Engelman 
       </surname> 
       <given-names>
         JA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zejnullahu 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mitsudomi 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Song 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hyland 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Park 
       </surname> 
       <given-names>
         JO 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lindeman 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gale 
       </surname> 
       <given-names>
         CM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhao 
       </surname> 
       <given-names>
         X 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Christensen 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kosaka 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Holmes 
       </surname> 
       <given-names>
         AJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rogers 
       </surname> 
       <given-names>
         AM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cappuzzo 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mok 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Johnson 
       </surname> 
       <given-names>
         BE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cantley 
       </surname> 
       <given-names>
         LC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Janne 
       </surname> 
       <given-names>
         PA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling 
     </article-h3> 
     <source />Science 
     <year>
       2007 
     </year> 
     <volume>
       316 
     </volume> 
     <fpage>
       1039 
     </fpage> 
     <lpage>
       1043 
     </lpage> 
     <!--PubMed citation query: 'Science||316|1039||bib13|'--> 
     <pub-id pub-id-type="pmid">
       17463250 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib14"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Fujimoto 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wislez 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhang 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Iwanaga 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dackor 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hanna 
       </surname> 
       <given-names>
         AE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kalyankrishna 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cody 
       </surname> 
       <given-names>
         DD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Price 
       </surname> 
       <given-names>
         RE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sato 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shay 
       </surname> 
       <given-names>
         JW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Minna 
       </surname> 
       <given-names>
         JD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Peyton 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tang 
       </surname> 
       <given-names>
         X 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Massarelli 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Herbst 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Threadgill 
       </surname> 
       <given-names>
         DW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wistuba 
       </surname> 
       <given-names>
         II 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kurie 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2005 
     </year> 
     <volume>
       65 
     </volume> 
     <fpage>
       11478 
     </fpage> 
     <lpage>
       11485 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||65|11478||bib14|'--> 
     <pub-id pub-id-type="pmid">
       16357156 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib15"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Garnis 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lockwood 
       </surname> 
       <given-names>
         WW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vucic 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ge 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Girard 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Minna 
       </surname> 
       <given-names>
         JD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gazdar 
       </surname> 
       <given-names>
         AF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lam 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         MacAulay 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lam 
       </surname> 
       <given-names>
         WL 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       2006 
     </year> 
     <volume>
       118 
     </volume> 
     <fpage>
       1556 
     </fpage> 
     <lpage>
       1564 
     </lpage> 
     <!--PubMed citation query: 'Int J Cancer||118|1556||bib15|'--> 
     <pub-id pub-id-type="pmid">
       16187286 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib16"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Gazdar 
       </surname> 
       <given-names>
         AF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Minna 
       </surname> 
       <given-names>
         JD 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Inhibition of EGFR signaling: all mutations are not created equal 
     </article-h3> 
     <source />PLoS Med 
     <year>
       2005 
     </year> 
     <volume>
       2 
     </volume> 
     <fpage>
       e377 
     </fpage> 
     <!--PubMed citation query: 'PLoS Med||2|e377||bib16|'--> 
     <pub-id pub-id-type="pmid">
       16288556 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib17"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Han 
       </surname> 
       <given-names>
         SW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hwang 
       </surname> 
       <given-names>
         PG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chung 
       </surname> 
       <given-names>
         DH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         DW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Im 
       </surname> 
       <given-names>
         SA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         YT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         TY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Heo 
       </surname> 
       <given-names>
         DS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bang 
       </surname> 
       <given-names>
         YJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         NK 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       2005 
     </year> 
     <volume>
       113 
     </volume> 
     <fpage>
       109 
     </fpage> 
     <lpage>
       115 
     </lpage> 
     <!--PubMed citation query: 'Int J Cancer||113|109||bib17|'--> 
     <pub-id pub-id-type="pmid">
       15386420 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib18"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Han 
       </surname> 
       <given-names>
         SW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         TY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jeon 
       </surname> 
       <given-names>
         YK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hwang 
       </surname> 
       <given-names>
         PG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Im 
       </surname> 
       <given-names>
         SA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         KH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         JH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         DW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Heo 
       </surname> 
       <given-names>
         DS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         NK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chung 
       </surname> 
       <given-names>
         DH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bang 
       </surname> 
       <given-names>
         YJ 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2006 
     </year> 
     <volume>
       12 
     </volume> 
     <fpage>
       2538 
     </fpage> 
     <lpage>
       2544 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||12|2538||bib18|'--> 
     <pub-id pub-id-type="pmid">
       16638863 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib19"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Hirsch 
       </surname> 
       <given-names>
         FR 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       EGFR: a prognostic and/or a predictive marker 
     </article-h3> 
     <source />J Thorac Oncol 
     <year>
       2006 
     </year> 
     <volume>
       1 
     </volume> 
     <fpage>
       395 
     </fpage> 
     <lpage>
       397 
     </lpage> 
     <!--PubMed citation query: 'J Thorac Oncol||1|395||bib19|'--> 
     <pub-id pub-id-type="pmid">
       17409888 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib20"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Hirsch 
       </surname> 
       <given-names>
         FR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Varella-Garcia 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bunn 
       </surname> 
       <given-names>
         PA 
       </given-names> 
       <suffix>
         Jr 
       </suffix> 
      </name> 
      <name> 
       <surname>
         Franklin 
       </surname> 
       <given-names>
         WA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dziadziuszko 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Thatcher 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chang 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Parikh 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pereira 
       </surname> 
       <given-names>
         JR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ciuleanu 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         von Pawel 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Watkins 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Flannery 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ellison 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Donald 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Knight 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Parums 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Botwood 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Holloway 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer 
     </article-h3> 
     <source />J Clin Oncol 
     <year>
       2006 
     </year> 
     <volume>
       24 
     </volume> 
     <fpage>
       5034 
     </fpage> 
     <lpage>
       5042 
     </lpage> 
     <!--PubMed citation query: 'J Clin Oncol||24|5034||bib20|'--> 
     <pub-id pub-id-type="pmid">
       17075123 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib21"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Hirsch 
       </surname> 
       <given-names>
         FR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Varella-Garcia 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         McCoy 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         West 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Xavier 
       </surname> 
       <given-names>
         AC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gumerlock 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bunn 
       </surname> 
       <given-names>
         PA 
       </given-names> 
       <suffix>
         Jr 
       </suffix> 
      </name> 
      <name> 
       <surname>
         Franklin 
       </surname> 
       <given-names>
         WA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Crowley 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gandara 
       </surname> 
       <given-names>
         DR 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Increased epidermal growth factor receptor gene copy number detected by fluorescence 
      <italic>
        in situ 
      </italic> hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study 
     </article-h3> 
     <source />J Clin Oncol 
     <year>
       2005 
     </year> 
     <volume>
       23 
     </volume> 
     <fpage>
       6838 
     </fpage> 
     <lpage>
       6845 
     </lpage> 
     <!--PubMed citation query: 'J Clin Oncol||23|6838||bib21|'--> 
     <pub-id pub-id-type="pmid">
       15998906 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib22"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Hsieh 
       </surname> 
       <given-names>
         MH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fang 
       </surname> 
       <given-names>
         YF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chang 
       </surname> 
       <given-names>
         WC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kuo 
       </surname> 
       <given-names>
         HP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lin 
       </surname> 
       <given-names>
         SY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         HP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         CL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         HC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ku 
       </surname> 
       <given-names>
         YC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         YT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chang 
       </surname> 
       <given-names>
         YH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         YT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hsi 
       </surname> 
       <given-names>
         BL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsai 
       </surname> 
       <given-names>
         SF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Huang 
       </surname> 
       <given-names>
         SF 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer 
     </article-h3> 
     <source />Lung Cancer 
     <year>
       2006 
     </year> 
     <volume>
       53 
     </volume> 
     <supplement>
       3 
     </supplement> 
     <fpage>
       311 
     </fpage> 
     <lpage>
       322 
     </lpage> 
     <!--PubMed citation query: 'Lung Cancer||53|311||bib22|'--> 
     <pub-id pub-id-type="pmid">
       16870303 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib23"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Hynes 
       </surname> 
       <given-names>
         RO 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants or both 
     </article-h3> 
     <source />Cell 
     <year>
       2003 
     </year> 
     <volume>
       113 
     </volume> 
     <fpage>
       821 
     </fpage> 
     <lpage>
       823 
     </lpage> 
     <!--PubMed citation query: 'Cell||113|821||bib23|'--> 
     <pub-id pub-id-type="pmid">
       12837240 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib24"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Italiano 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vandenbos 
       </surname> 
       <given-names>
         FB 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Otto 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mouroux 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fontaine 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Marcy 
       </surname> 
       <given-names>
         PY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cardot 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Thyss 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pedeutour 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors 
     </article-h3> 
     <source />Ann Oncol 
     <year>
       2006 
     </year> 
     <volume>
       17 
     </volume> 
     <fpage>
       981 
     </fpage> 
     <lpage>
       985 
     </lpage> 
     <!--PubMed citation query: 'Ann Oncol||17|981||bib24|'--> 
     <pub-id pub-id-type="pmid">
       16524970 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib25"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Koutsopoulos 
       </surname> 
       <given-names>
         AV 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mavroudis 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dambaki 
       </surname> 
       <given-names>
         KI 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Souglakos 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tzortzaki 
       </surname> 
       <given-names>
         EG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Drositis 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Delides 
       </surname> 
       <given-names>
         GS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Georgoulias 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stathopoulos 
       </surname> 
       <given-names>
         EN 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome 
     </article-h3> 
     <source />Lung Cancer 
     <year>
       2007 
     </year> 
     <volume>
       57 
     </volume> 
     <supplement>
       2 
     </supplement> 
     <fpage>
       193 
     </fpage> 
     <lpage>
       200 
     </lpage> 
     <!--PubMed citation query: 'Lung Cancer||57|193||bib25|'--> 
     <pub-id pub-id-type="pmid">
       17442448 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib26"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Li 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rosell 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Urban 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Font 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ariza 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Armengol 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Abad 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Navas 
       </surname> 
       <given-names>
         JJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Monzo 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma 
     </article-h3> 
     <source />Lung Cancer 
     <year>
       1994 
     </year> 
     <volume>
       11 
     </volume> 
     <fpage>
       19 
     </fpage> 
     <lpage>
       27 
     </lpage> 
     <!--PubMed citation query: 'Lung Cancer||11|19||bib26|'--> 
     <pub-id pub-id-type="pmid">
       8081702 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib27"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Purvis 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shih 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weinstein 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Agrawal 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Radhakrishnan 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations 
     </article-h3> 
     <source />Ann Biomed Eng 
     <year>
       2007 
     </year> 
     <volume>
       35 
     </volume> 
     <fpage>
       1012 
     </fpage> 
     <lpage>
       1025 
     </lpage> 
     <!--PubMed citation query: 'Ann Biomed Eng||35|1012||bib27|'--> 
     <pub-id pub-id-type="pmid">
       17273938 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib28"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Lutterbach 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zeng 
       </surname> 
       <given-names>
         Q 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Davis 
       </surname> 
       <given-names>
         LJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hatch 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hang 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kohl 
       </surname> 
       <given-names>
         NE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gibbs 
       </surname> 
       <given-names>
         JB 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pan 
       </surname> 
       <given-names>
         BS 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2007 
     </year> 
     <volume>
       67 
     </volume> 
     <fpage>
       2081 
     </fpage> 
     <lpage>
       2088 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||67|2081||bib28|'--> 
     <pub-id pub-id-type="pmid">
       17332337 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib29"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Lynch 
       </surname> 
       <given-names>
         TJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bell 
       </surname> 
       <given-names>
         DW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sordella 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gurubhagavatula 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Okimoto 
       </surname> 
       <given-names>
         RA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Brannigan 
       </surname> 
       <given-names>
         BW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Harris 
       </surname> 
       <given-names>
         PL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haserlat 
       </surname> 
       <given-names>
         SM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Supko 
       </surname> 
       <given-names>
         JG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haluska 
       </surname> 
       <given-names>
         FG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Louis 
       </surname> 
       <given-names>
         DN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Christiani 
       </surname> 
       <given-names>
         DC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Settleman 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haber 
       </surname> 
       <given-names>
         DA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib 
     </article-h3> 
     <source />N Engl J Med 
     <year>
       2004 
     </year> 
     <volume>
       350 
     </volume> 
     <fpage>
       2129 
     </fpage> 
     <lpage>
       2139 
     </lpage> 
     <!--PubMed citation query: 'N Engl J Med||350|2129||bib29|'--> 
     <pub-id pub-id-type="pmid">
       15118073 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib30"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Marsit 
       </surname> 
       <given-names>
         CJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hasegawa 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hirao 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         DH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Aldape 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hinds 
       </surname> 
       <given-names>
         PW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wiencke 
       </surname> 
       <given-names>
         JK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nelson 
       </surname> 
       <given-names>
         HH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kelsey 
       </surname> 
       <given-names>
         KT 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2004 
     </year> 
     <volume>
       64 
     </volume> 
     <fpage>
       8702 
     </fpage> 
     <lpage>
       8707 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||64|8702||bib30|'--> 
     <pub-id pub-id-type="pmid">
       15574780 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib31"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Matsumoto 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Takahashi 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Iwakawa 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Matsuno 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nakanishi 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kohno 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shimizu 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yokota 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Frequent EGFR mutations in brain metastases of lung adenocarcinoma 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       2006 
     </year> 
     <volume>
       119 
     </volume> 
     <fpage>
       1491 
     </fpage> 
     <lpage>
       1494 
     </lpage> 
     <!--PubMed citation query: 'Int J Cancer||119|1491||bib31|'--> 
     <pub-id pub-id-type="pmid">
       16642476 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib32"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Paez 
       </surname> 
       <given-names>
         JG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Janne 
       </surname> 
       <given-names>
         PA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         JC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tracy 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Greulich 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gabriel 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Herman 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kaye 
       </surname> 
       <given-names>
         FJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lindeman 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Boggon 
       </surname> 
       <given-names>
         TJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Naoki 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sasaki 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fujii 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Eck 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sellers 
       </surname> 
       <given-names>
         WR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Johnson 
       </surname> 
       <given-names>
         BE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Meyerson 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy 
     </article-h3> 
     <source />Science 
     <year>
       2004 
     </year> 
     <volume>
       304 
     </volume> 
     <fpage>
       1497 
     </fpage> 
     <lpage>
       1500 
     </lpage> 
     <!--PubMed citation query: 'Science||304|1497||bib32|'--> 
     <pub-id pub-id-type="pmid">
       15118125 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib33"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Pallis 
       </surname> 
       <given-names>
         AG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Voutsina 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kalikaki 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Souglakos 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Briasoulis 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Murray 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Koutsopoulos 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tripaki 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stathopoulos 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mavroudis 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Georgoulias 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       ‘Classical' but not ‘other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer 
     </article-h3> 
     <source />Br J Cancer 
     <year>
       2007 
     </year> 
     <volume>
       97 
     </volume> 
     <fpage>
       1560 
     </fpage> 
     <lpage>
       1566 
     </lpage> 
     <!--PubMed citation query: 'Br J Cancer||97|1560||bib33|'--> 
     <pub-id pub-id-type="pmid">
       18000506 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib34"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Pao 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wang 
       </surname> 
       <given-names>
         TY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Riely 
       </surname> 
       <given-names>
         GJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Miller 
       </surname> 
       <given-names>
         VA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pan 
       </surname> 
       <given-names>
         Q 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ladanyi 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zakowski 
       </surname> 
       <given-names>
         MF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Heelan 
       </surname> 
       <given-names>
         RT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kris 
       </surname> 
       <given-names>
         MG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Varmus 
       </surname> 
       <given-names>
         HE 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib 
     </article-h3> 
     <source />PLoS Med 
     <year>
       2005 
     </year> 
     <volume>
       2 
     </volume> 
     <fpage>
       e17 
     </fpage> 
     <!--PubMed citation query: 'PLoS Med||2|e17||bib34|'--> 
     <pub-id pub-id-type="pmid">
       15696205 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib35"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Papadopoulos 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kinzler 
       </surname> 
       <given-names>
         KW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vogelstein 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       The role of companion diagnostics in the development and use of mutation-targeted cancer therapies 
     </article-h3> 
     <source />Nat Biotechnol 
     <year>
       2006 
     </year> 
     <volume>
       24 
     </volume> 
     <fpage>
       985 
     </fpage> 
     <lpage>
       995 
     </lpage> 
     <!--PubMed citation query: 'Nat Biotechnol||24|985||bib35|'--> 
     <pub-id pub-id-type="pmid">
       16900147 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib36"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Perez-Soler 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chachoua 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hammond 
       </surname> 
       <given-names>
         LA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rowinsky 
       </surname> 
       <given-names>
         EK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Huberman 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Karp 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rigas 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Clark 
       </surname> 
       <given-names>
         GM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Santabarbara 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bonomi 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer 
     </article-h3> 
     <source />J Clin Oncol 
     <year>
       2004 
     </year> 
     <volume>
       22 
     </volume> 
     <fpage>
       3238 
     </fpage> 
     <lpage>
       3247 
     </lpage> 
     <!--PubMed citation query: 'J Clin Oncol||22|3238||bib36|'--> 
     <pub-id pub-id-type="pmid">
       15310767 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib37"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Sakurada 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lara-Guerra 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shepherd 
       </surname> 
       <given-names>
         FA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsao 
       </surname> 
       <given-names>
         MS 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Tissue heterogeneity of EGFR mutation in lung adenocarcinoma 
     </article-h3> 
     <source />J Thorac Oncol 
     <year>
       2008 
     </year> 
     <volume>
       3 
     </volume> 
     <fpage>
       527 
     </fpage> 
     <lpage>
       529 
     </lpage> 
     <!--PubMed citation query: 'J Thorac Oncol||3|527||bib37|'--> 
     <pub-id pub-id-type="pmid">
       18449007 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib38"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Sharma 
       </surname> 
       <given-names>
         SV 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bell 
       </surname> 
       <given-names>
         DW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Settleman 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haber 
       </surname> 
       <given-names>
         DA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Epidermal growth factor receptor mutations in lung cancer 
     </article-h3> 
     <source />Nat Rev Cancer 
     <year>
       2007 
     </year> 
     <volume>
       7 
     </volume> 
     <fpage>
       169 
     </fpage> 
     <lpage>
       181 
     </lpage> 
     <!--PubMed citation query: 'Nat Rev Cancer||7|169||bib38|'--> 
     <pub-id pub-id-type="pmid">
       17318210 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib39"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Sordella 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bell 
       </surname> 
       <given-names>
         DW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haber 
       </surname> 
       <given-names>
         DA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Settleman 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways 
     </article-h3> 
     <source />Science 
     <year>
       2004 
     </year> 
     <volume>
       305 
     </volume> 
     <fpage>
       1163 
     </fpage> 
     <lpage>
       1167 
     </lpage> 
     <!--PubMed citation query: 'Science||305|1163||bib39|'--> 
     <pub-id pub-id-type="pmid">
       15284455 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib40"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Takano 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ohe 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sakamoto 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsuta 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Matsuno 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tateishi 
       </surname> 
       <given-names>
         U 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yamamoto 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nokihara 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yamamoto 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sekine 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kunitoh 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shibata 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sakiyama 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yoshida 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tamura 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer 
     </article-h3> 
     <source />J Clin Oncol 
     <year>
       2005 
     </year> 
     <volume>
       23 
     </volume> 
     <fpage>
       6829 
     </fpage> 
     <lpage>
       6837 
     </lpage> 
     <!--PubMed citation query: 'J Clin Oncol||23|6829||bib40|'--> 
     <pub-id pub-id-type="pmid">
       15998907 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib41"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Taron 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ichinose 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rosell 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mok 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Massuti 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zamora 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mate 
       </surname> 
       <given-names>
         JL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Manegold 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ono 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Queralt 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jahan 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sanchez 
       </surname> 
       <given-names>
         JJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sanchez-Ronco 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hsue 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jablons 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sanchez 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Moran 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2005 
     </year> 
     <volume>
       11 
     </volume> 
     <fpage>
       5878 
     </fpage> 
     <lpage>
       5885 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||11|5878||bib41|'--> 
     <pub-id pub-id-type="pmid">
       16115929 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib42"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Tokumo 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Toyooka 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kiura 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shigematsu 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tomii 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Aoe 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ichimura 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsuda 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yano 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsukuda 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tabata 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ueoka 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tanimoto 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Date 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gazdar 
       </surname> 
       <given-names>
         AF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shimizu 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2005 
     </year> 
     <volume>
       11 
     </volume> 
     <fpage>
       1167 
     </fpage> 
     <lpage>
       1173 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||11|1167||bib42|'--> 
     <pub-id pub-id-type="pmid">
       15709185 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib43"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Tortola 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Steinert 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hantschick 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Peinado 
       </surname> 
       <given-names>
         MA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gastinger 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stosiek 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lippert 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schlegel 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Reymond 
       </surname> 
       <given-names>
         MA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer 
     </article-h3> 
     <source />J Clin Oncol 
     <year>
       2001 
     </year> 
     <volume>
       19 
     </volume> 
     <fpage>
       2837 
     </fpage> 
     <lpage>
       2843 
     </lpage> 
     <!--PubMed citation query: 'J Clin Oncol||19|2837||bib43|'--> 
     <pub-id pub-id-type="pmid">
       11387355 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib44"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Tsao 
       </surname> 
       <given-names>
         AS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tang 
       </surname> 
       <given-names>
         XM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sabloff 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Xiao 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shigematsu 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Roth 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Spitz 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hong 
       </surname> 
       <given-names>
         WK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gazdar 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wistuba 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer 
     </article-h3> 
     <source />J Thorac Oncol 
     <year>
       2006 
     </year> 
     <volume>
       1 
     </volume> 
     <fpage>
       231 
     </fpage> 
     <lpage>
       239 
     </lpage> 
     <!--PubMed citation query: 'J Thorac Oncol||1|231||bib44|'--> 
     <pub-id pub-id-type="pmid">
       17409862 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib45"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Tsao 
       </surname> 
       <given-names>
         MS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sakurada 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cutz 
       </surname> 
       <given-names>
         JC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhu 
       </surname> 
       <given-names>
         CQ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kamel-Reid 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Squire 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lorimer 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhang 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Daneshmand 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Marrano 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         da Cunha Santos 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lagarde 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Richardson 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Seymour 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Whitehead 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ding 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pater 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shepherd 
       </surname> 
       <given-names>
         FA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Erlotinib in lung cancer – molecular and clinical predictors of outcome 
     </article-h3> 
     <source />N Engl J Med 
     <year>
       2005 
     </year> 
     <volume>
       353 
     </volume> 
     <fpage>
       133 
     </fpage> 
     <lpage>
       144 
     </lpage> 
     <!--PubMed citation query: 'N Engl J Med||353|133||bib45|'--> 
     <pub-id pub-id-type="pmid">
       16014883 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib46"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         van ‘t Veer 
       </surname> 
       <given-names>
         LJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dai 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         van de Vijver 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         He 
       </surname> 
       <given-names>
         YD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hart 
       </surname> 
       <given-names>
         AA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mao 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Peterse 
       </surname> 
       <given-names>
         HL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         van der Kooy 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Marton 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Witteveen 
       </surname> 
       <given-names>
         AT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schreiber 
       </surname> 
       <given-names>
         GJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kerkhoven 
       </surname> 
       <given-names>
         RM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Roberts 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Linsley 
       </surname> 
       <given-names>
         PS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bernards 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Friend 
       </surname> 
       <given-names>
         SH 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Gene expression profiling predicts clinical outcome of breast cancer 
     </article-h3> 
     <source />Nature 
     <year>
       2002 
     </year> 
     <volume>
       415 
     </volume> 
     <fpage>
       530 
     </fpage> 
     <lpage>
       536 
     </lpage> 
     <!--PubMed citation query: 'Nature||415|530||bib46|'--> 
     <pub-id pub-id-type="pmid">
       11823860 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib47"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         van Zandwijk 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mathy 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Boerrigter 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ruijter 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tielen 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         de Jong 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Baas 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Burgers 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nederlof 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer 
     </article-h3> 
     <source />Ann Oncol 
     <year>
       2007 
     </year> 
     <volume>
       18 
     </volume> 
     <fpage>
       99 
     </fpage> 
     <lpage>
       103 
     </lpage> 
     <!--PubMed citation query: 'Ann Oncol||18|99||bib47|'--> 
     <pub-id pub-id-type="pmid">
       17060486 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib48"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Van't Veer 
       </surname> 
       <given-names>
         LJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weigelt 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Road map to metastasis 
     </article-h3> 
     <source />Nat Med 
     <year>
       2003 
     </year> 
     <volume>
       9 
     </volume> 
     <fpage>
       999 
     </fpage> 
     <lpage>
       1000 
     </lpage> 
     <!--PubMed citation query: 'Nat Med||9|999||bib48|'--> 
    </citation> 
   </ref> 
   <ref id="bib49"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Yokota 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kohno 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Molecular footprints of human lung cancer progression 
     </article-h3> 
     <source />Cancer Sci 
     <year>
       2004 
     </year> 
     <volume>
       95 
     </volume> 
     <fpage>
       197 
     </fpage> 
     <lpage>
       204 
     </lpage> 
     <!--PubMed citation query: 'Cancer Sci||95|197||bib49|'--> 
     <pub-id pub-id-type="pmid">
       15016317 
     </pub-id> 
    </citation> 
   </ref> 
  </ref-list> 
 </back> 
 <floats-wrap> 
  <table-wrap id="tbl1" position="float"> 
   <label>Table 1</label> 
   <p content-type="table-h3">Patient's clinicopathological characteristics</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="left" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Case 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Age 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Sex 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Histology 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Stage 
        <sup>a</sup> 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Smoking status 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Tissue sample 
        <sup>b</sup> P 
        <sup>c</sup>/M 
        <sup>d</sup> 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Metastatic site 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Time 
        <sup>e</sup> elapsed between P and M 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Treatment administered between P and M 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 1</td> 
      <td align="center" charoff="50" valign="top">60</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">B/B</td> 
      <td align="left" charoff="50" valign="top">Skin</td> 
      <td align="center" charoff="50" valign="top">10</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 2</td> 
      <td align="center" charoff="50" valign="top">54</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">SCC</td> 
      <td align="center" charoff="50" valign="top">II</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/S</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">20</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 3</td> 
      <td align="center" charoff="50" valign="top">70</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Former</td> 
      <td align="left" charoff="50" valign="top">B/B</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">55</td> 
      <td align="left" charoff="50" valign="top">Taxane–gemcitabine</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 4</td> 
      <td align="center" charoff="50" valign="top">44</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">65</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum–gemcitabine</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 5</td> 
      <td align="center" charoff="50" valign="top">55</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/S</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">23</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 6</td> 
      <td align="center" charoff="50" valign="top">63</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">B/B</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">4</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 7</td> 
      <td align="center" charoff="50" valign="top">66</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC/BAC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Never</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Thoracic wall</td> 
      <td align="center" charoff="50" valign="top">12</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 8</td> 
      <td align="center" charoff="50" valign="top">57</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">LCC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Thoracic wall</td> 
      <td align="center" charoff="50" valign="top">4</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 9</td> 
      <td align="center" charoff="50" valign="top">55</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Former</td> 
      <td align="left" charoff="50" valign="top">S/S</td> 
      <td align="left" charoff="50" valign="top">Thoracic wall</td> 
      <td align="center" charoff="50" valign="top">15</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">10</td> 
      <td align="center" charoff="50" valign="top">49</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">II</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/S</td> 
      <td align="left" charoff="50" valign="top">Adrenal gland</td> 
      <td align="center" charoff="50" valign="top">28</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">11</td> 
      <td align="center" charoff="50" valign="top">50</td> 
      <td align="center" charoff="50" valign="top">F</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">B/B</td> 
      <td align="left" charoff="50" valign="top">Brain</td> 
      <td align="center" charoff="50" valign="top">36</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">12</td> 
      <td align="center" charoff="50" valign="top">68</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/S</td> 
      <td align="left" charoff="50" valign="top">Brain</td> 
      <td align="center" charoff="50" valign="top">10</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">13</td> 
      <td align="center" charoff="50" valign="top">44</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">GCC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">B/B</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">74</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">14</td> 
      <td align="center" charoff="50" valign="top">56</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">B/S</td> 
      <td align="left" charoff="50" valign="top">Adrenal gland</td> 
      <td align="center" charoff="50" valign="top">17</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">15</td> 
      <td align="center" charoff="50" valign="top">53</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Thoracic wall</td> 
      <td align="center" charoff="50" valign="top">2</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">16</td> 
      <td align="center" charoff="50" valign="top">41</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">143</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">17</td> 
      <td align="center" charoff="50" valign="top">56</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Former</td> 
      <td align="left" charoff="50" valign="top">B/S</td> 
      <td align="left" charoff="50" valign="top">Adrenal gland</td> 
      <td align="center" charoff="50" valign="top">36</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum–gemcitabine, gefitinib</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">18</td> 
      <td align="center" charoff="50" valign="top">42</td> 
      <td align="center" charoff="50" valign="top">F</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">II</td> 
      <td align="left" charoff="50" valign="top">Never</td> 
      <td align="left" charoff="50" valign="top">S/S</td> 
      <td align="left" charoff="50" valign="top">Liver</td> 
      <td align="center" charoff="50" valign="top">30</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum, gefitinib</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">19</td> 
      <td align="center" charoff="50" valign="top">55</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Former</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Bone</td> 
      <td align="center" charoff="50" valign="top">2</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">20</td> 
      <td align="center" charoff="50" valign="top">46</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">SCC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">45</td> 
      <td align="left" charoff="50" valign="top">Taxane–platinum–gefitinib</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">21</td> 
      <td align="center" charoff="50" valign="top">62</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">LCC</td> 
      <td align="center" charoff="50" valign="top">III</td> 
      <td align="left" charoff="50" valign="top">Never</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Bone</td> 
      <td align="center" charoff="50" valign="top">48</td> 
      <td align="left" charoff="50" valign="top">Platinum–gemcitabine</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">22</td> 
      <td align="center" charoff="50" valign="top">67</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">B/S</td> 
      <td align="left" charoff="50" valign="top">Adrenal gland</td> 
      <td align="center" charoff="50" valign="top">14</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">23</td> 
      <td align="center" charoff="50" valign="top">53</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/B</td> 
      <td align="left" charoff="50" valign="top">Brain</td> 
      <td align="center" charoff="50" valign="top">21</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">24</td> 
      <td align="center" charoff="50" valign="top">52</td> 
      <td align="center" charoff="50" valign="top">F</td> 
      <td align="left" charoff="50" valign="top">ADC/BAC</td> 
      <td align="center" charoff="50" valign="top">II</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">S/S</td> 
      <td align="left" charoff="50" valign="top">Lung</td> 
      <td align="center" charoff="50" valign="top">51</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">25</td> 
      <td align="center" charoff="50" valign="top">63</td> 
      <td align="center" charoff="50" valign="top">M</td> 
      <td align="left" charoff="50" valign="top">ADC</td> 
      <td align="center" charoff="50" valign="top">IV</td> 
      <td align="left" charoff="50" valign="top">Active</td> 
      <td align="left" charoff="50" valign="top">B/B</td> 
      <td align="left" charoff="50" valign="top">Thoracic wall</td> 
      <td align="center" charoff="50" valign="top">1</td> 
      <td align="left" charoff="50" valign="top">None</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="t1-fn1"> 
     <label></label> 
     <p>ADC=adenocarcinoma; ADC/BAC=adenocarcinoma with bronchoalveolar features; GCC=giant cell carcinoma; LCC=large cell carcinoma; F=female; M=male; SCC=squamous carcinoma.</p> 
    </fn> 
    <fn id="t1-fn2"> 
     <label>a</label> 
     <p>Stage, corresponds to that of the time of primary diagnosis.</p> 
    </fn> 
    <fn id="t1-fn3"> 
     <label>b</label> 
     <p>Tissue sample: B, biopsy; S, surgery.</p> 
    </fn> 
    <fn id="t1-fn4"> 
     <label>c</label> 
     <p>P, primary tumour.</p> 
    </fn> 
    <fn id="t1-fn5"> 
     <label>d</label> 
     <p>M, metastasis.</p> 
    </fn> 
    <fn id="t1-fn6"> 
     <label>e</label> 
     <p>Time, months.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
  <table-wrap id="tbl2" position="float"> 
   <label>Table 2</label> 
   <p content-type="table-h3"> 
    <italic>
      EGFR 
    </italic> and 
    <italic>
      K-RAS 
    </italic> status in paired primary and metastatic tumours</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="left" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" colspan="2" valign="top"> 
       <bold> 
        <italic>
          EGFR 
        </italic> mutation status 
       </bold> 
       <hr /> </th> 
      <th align="center" charoff="50" colspan="2" valign="top"> 
       <bold>
         EGFR expression 
       </bold> 
       <hr /> </th> 
      <th align="center" charoff="50" colspan="2" valign="top"> 
       <bold>
         p-EGFR expression 
       </bold> 
       <hr /> </th> 
      <th align="center" charoff="50" colspan="2" valign="top"> 
       <bold> 
        <italic>
          K-RAS 
        </italic> mutation status 
       </bold> 
       <hr /> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Case 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Primary 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Metastasis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Primary 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Metastasis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Primary 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Metastasis 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Primary 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Metastasis 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Gefitinib 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Response 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 1</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 2</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">3+</td> 
      <td align="center" charoff="50" valign="top">3+</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 3</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 4</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">3+</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 5</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 6</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 7</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 8</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">G12S</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 9</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">G13S</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">10</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="center" charoff="50" valign="top">3+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">G12V</td> 
      <td align="left" charoff="50" valign="top">G12V</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">11</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">G12S</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">12</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">L692P V717A</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">13</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">T847A</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">14</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">3+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">PD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">15</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">PD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">16</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">G12A</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">PD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">17</td> 
      <td align="left" charoff="50" valign="top">L692P</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">SD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">18</td> 
      <td align="left" charoff="50" valign="top">E746V</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">SD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">19</td> 
      <td align="left" charoff="50" valign="top">G857E</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="center" charoff="50" valign="top">1+</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">SD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">20</td> 
      <td align="left" charoff="50" valign="top">E746-A750 del</td> 
      <td align="left" charoff="50" valign="top">E746-A750 del T790M</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="center" charoff="50" valign="top">3+</td> 
      <td align="center" charoff="50" valign="top">2+</td> 
      <td align="center" charoff="50" valign="top">0</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">SD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">21</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">22</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="left" charoff="50" valign="top">G12D</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">PD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">23</td> 
      <td align="left" charoff="50" valign="top">E746-A750 del</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="left" charoff="50" valign="top">G12C</td> 
      <td align="left" charoff="50" valign="top">G12C</td> 
      <td align="left" charoff="50" valign="top">Yes</td> 
      <td align="left" charoff="50" valign="top">SD</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">24</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">25</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="center" charoff="50" valign="top">ND</td> 
      <td align="left" charoff="50" valign="top">G12C</td> 
      <td align="left" charoff="50" valign="top">wt</td> 
      <td align="left" charoff="50" valign="top">No</td> 
      <td align="left" charoff="50" valign="top">—</td> 
     </tr> 
    </tbody> 
   </table> 
  </table-wrap> 
  <table-wrap id="tbl3" position="float"> 
   <label>Table 3</label> 
   <p content-type="table-h3">Combined analysis of 
    <italic>
      EGFR 
    </italic> and 
    <italic>
      K-RAS 
    </italic> mutation status</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" colspan="4" valign="top"> 
       <bold>
         Primary/metastatic tumour 
       </bold> 
       <hr /> </th> 
      <th align="center" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         wt/wt 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         wt/mut 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         mut/wt 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         mut/mut 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Discordance 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top">EGFR</td> 
      <td align="center" charoff="50" valign="top">18 (72%)</td> 
      <td align="center" charoff="50" valign="top">2 (8%)</td> 
      <td align="center" charoff="50" valign="top">4 (16%)</td> 
      <td align="center" charoff="50" valign="top">1 (4%)<sup>a</sup></td> 
      <td align="center" charoff="50" valign="top">7 cases (28%)</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">K-RAS</td> 
      <td align="center" charoff="50" valign="top">17 (68%)</td> 
      <td align="center" charoff="50" valign="top">3 (12%)</td> 
      <td align="center" charoff="50" valign="top">3 (12%)</td> 
      <td align="center" charoff="50" valign="top">2 (8%)</td> 
      <td align="center" charoff="50" valign="top">6 cases (24%)</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="t3-fn1"> 
     <label>a</label> 
     <p>Del19/Del19 and T790M.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
  <table-wrap id="tbl4" position="float"> 
   <label>Table 4</label> 
   <p content-type="table-h3">EGFR expression as assessed by IHC</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" colspan="4" valign="top"> 
       <bold>
         Primary tumour status/metastasis status 
       </bold> 
       <hr /> </th> 
      <th align="center" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         +ve/+ve 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         ?ve/?ve 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         +ve/?ve 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         ?ve/+ve 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Discordance 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top">EGFR</td> 
      <td align="center" charoff="50" valign="top">4 (21.1%)</td> 
      <td align="center" charoff="50" valign="top">13 (68.4%)</td> 
      <td align="center" charoff="50" valign="top">1 (5.3%)</td> 
      <td align="center" charoff="50" valign="top">1 (5.3%)</td> 
      <td align="center" charoff="50" valign="top">2/19 (10.6%)</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">p-EGFR (Y1173)</td> 
      <td align="center" charoff="50" valign="top">1 (6.2%)</td> 
      <td align="center" charoff="50" valign="top">7 (43.8%)</td> 
      <td align="center" charoff="50" valign="top">2 (12.5%)</td> 
      <td align="center" charoff="50" valign="top">6 (37.5%)</td> 
      <td align="center" charoff="50" valign="top">8/16 (50%)</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="t4-fn1"> 
     <label></label> 
     <p>IHC=immunohistochemistry.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
 </floats-wrap> 
</article>